Gemcitabine/Irinotecan/celecoxib in pancreatic cancer.

Oncology (Williston Park, N.Y.)

Volumn 18, Issue 14 Suppl 14, 2004, Pages 43-45

  Lipton, Allan ^a   Harvey, Harold ^a   Witters, Lois ^a   Kerr, Samuel ^a   Legore, Kathryn ^a   Campbell, Cynthia ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; CAMPTOTHECIN; CELECOXIB; DEOXYCYTIDINE; DRUG DERIVATIVE; GEMCITABINE; IRINOTECAN; PROSTAGLANDIN SYNTHASE INHIBITOR; PYRAZOLE DERIVATIVE; SULFONAMIDE;

AGED; ARTICLE; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; DOSE RESPONSE; DRUG ADMINISTRATION; FEMALE; HUMAN; MALE; MIDDLE AGED; NEUTROPENIA; PANCREAS TUMOR; PATHOLOGY; TIME; TREATMENT OUTCOME;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CYCLOOXYGENASE INHIBITORS; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUTROPENIA; PANCREATIC NEOPLASMS; PYRAZOLES; SULFONAMIDES; TIME FACTORS; TREATMENT OUTCOME;

EID: 17944366947     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (0)